803686-10-4Relevant academic research and scientific papers
Preparation of 3-(4-chlorophenyl)-2-(2-aminothiazol-4-yl)-5-methoxybenzo[b] furan derivatives and their leukotriene B4 inhibitory activity
Sakata, Yoko,Kuramoto, Mari,Ando, Kumiko,Yamaguchi, Mami,Kawasaki, Ikuo,Kunitomo, Jun-Ichi,Yokomizo, Takehiko,Ohishi, Yoshitaka
, p. 3083 - 3086 (2007)
A series of 3-(4-chlorophenyl)-2-(2-aminothiazol-4-yl)benzo[b]furan derivatives 6-10 were prepared and their leukotriene B4 inhibitory activity was evaluated. We found that several compounds showed strong inhibition of calcium mobilization in C
Preparation of leukotriene B4 inhibitory active 2- and 3-(2-aminothiazol-4-yl)benzo[b]furan derivatives and their growth inhibitory activity on human pancreatic cancer cells
Kuramoto, Mari,Sakata, Yoko,Terai, Kumi,Kawasaki, Ikuo,Kunitomo, Jun-Ichi,Ohishi, Takahiro,Yokomizo, Takehiko,Takeda, Seiichi,Tanaka, Shuichi,Ohishi, Yoshitaka
experimental part, p. 2772 - 2781 (2009/02/02)
A series of 2-(2-aminothiazol-4-yl)benzo[b]furan and 3-(2-aminothiazol-4- yl)benzo[b]furan derivatives were prepared, and their leukotriene B4 inhibitory activity and growth inhibitory activity in cancer cell lines were evaluated. Several compounds showed strong inhibition of calcium mobilization in CHO cells overexpressing human BLT1 and BLT2 receptors and growth inhibition to human pancreatic cancer cells MIA PaCa-2. 3-(4-Chlorophenyl)-2-[5-formyl-2-[(dimethylamino)methyleneamino]thiazol-4-yl] -5-methoxybenzo[b]furan 8b showed the most potent and selective inhibition for the human BLT2 receptor, and its IC50 value was smaller than that of the selected positive control compound, ZK-158252. 3-(4-Chlorophenyl)-2-[2-[(dimethylamino)methyleneamino]-5-(2- hydroxyethyliminomethyl)thiazol-4-yl]-5-methoxybenzo[b]furan 9a displayed growth inhibitory activity towards MIA PaCa-2. The Royal Society of Chemistry.
BENZOFURAN COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME
-
Page/Page column 61, (2008/06/13)
The present invention relates to a benzofuran compound of the formula (I) wherein each symbol is as defined in the description, a pharmaceutically acceptable salt thereof and the like. The compound of the present invention has superior leukotriene inhibitory action, BLT2 competitive inhibitory action, BLT2 blocking action, action for the prophylaxis or treatment of allergy, action for the prophylaxis or treatment of asthma and action for the prophylaxis or treatment of inflammation, and is useful as an agent for the prophylaxis or treatment of diseases such as allergic disease, asthma, inflammation and the like, and other diseases.
